ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
ADIA Nutrition (OTCQB: ADIA) submitted its complete, patent-pending regenerative protocol for pediatric Autism Spectrum Disorder to an independent Institutional Review Board on November 24, 2025 after the IRB accepted the company's initial draft and invited a final version.
The filing includes detailed methodology, safety measures, dosing regimen, and clinical endpoints and is under expert evaluation; IRB acceptance would authorize ADIA's first-ever IRB-approved human study using antioxidants and stem cells in children with ASD. The protocol remains confidential while intellectual property and clinical pathways advance; the company said a larger update will follow the IRB determination.
ADIA Nutrition (OTCQB: ADIA) will host a live webinar on Thursday, November 20, 2025 at 6:30 PM EST on Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis and other autoimmune conditions.
Dr. Evan Thomas, MD, PhD, medical director of Adia Med HSCT Program, will discuss the science, patient outcomes, and Adia Med’s physician-led approach. Registration is available via Zoom and interested parties can contact CEO Larry Powalisz for more information or partnership inquiries.
ADIA Nutrition (OTCQB: ADIA) filed with the SEC and OTC Markets on November 17, 2025 to update its Standard Industrial Classification to 2836 (Biological Products, Except Diagnostic), replacing prior codes 2834 and 6719 to better reflect its biologics manufacturing and clinic operations.
The company noted Adia Labs sells FDA-registered 361 HCT/Ps (AdiaVita, AdiaLink) nationwide and Adia Med clinics provide regenerative treatments. The change will take effect on ADIA's next filings. ADIA also highlighted 200%+ Q3 2025 revenue growth, OTCQB uplisting progress, and an expanding clinic network.
ADIA Nutrition (OTCQB: ADIA) filed a provisional patent application with the United States Patent and Trademark Office on November 12, 2025 for a novel medical protocol aimed at enhancing regenerative outcomes.
The patent pending protocol reportedly uses unique procedural and biological mechanisms and gives ADIA a 12-month window to advance research, partnerships, and commercialization while preserving strategic confidentiality.
The company invited clinic owners and healthcare practitioners to inquire about licensing and integration of its regenerative therapies and said further updates will follow as development progresses.
Adia Nutrition (OTCQB: ADIA) announced a strategic partnership between its research arm Adia Labs and AxiaMD on November 10, 2025.
Under the agreement, AxiaMD's nationwide physician-oversight network will offer Adia Labs' regenerative products to clients while Adia's clinics gain AxiaMD's compliance and oversight services across all 50 states, enabling chiropractic clinics to perform advanced regenerative procedures under full physician oversight. The release highlights FDA-compliant stem cell products, a mutual referral model, and prior company momentum including 200%+ Q3 2025 revenue growth and an OTCQB uplisting toward Nasdaq eligibility.
Adia Nutrition (OTCQB: ADIA) summarized 2025 milestones including a confirmed 200%+ Q3 revenue surge quarter-over-quarter with profit margins above 20%, accelerated commercial expansion, and steps toward Nasdaq uplisting. The company said it will file a Form 10 by end of November 2025 (SEC review period ~60 days) and expects Form 10 effectiveness by late January 2026. Other highlights: sales force tripled with four regional divisions, preferred‑vendor access to >4,000 personal injury physicians, progress toward insurer in‑network status, and a divestiture of Biolete Coffee while retaining an 18% equity stake.
Adia Nutrition (OTCQB: ADIA) announced an early release of its Q3 financial results on October 28, 2025, issued weeks ahead of schedule.
The company reported revenue growth of over 200% versus the prior quarter and a net profit margin of greater than 20%. Management said results exceeded prior forecasts and highlighted operational execution, product momentum, and a focus on stakeholder value. The release invites investors and partners to view the full Q3 financial report and contact CEO Larry Powalisz for inquiries or licensing and partnership opportunities.
Adia Nutrition (OTCQB: ADIA) appointed Dr. Evan Thomas, MD, PhD as Independent Medical Director for its medical division, Adia Med, effective October 21, 2025. Dr. Thomas will oversee clinic practices and clinical operations, including finalizing protocols for the Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program pending in-network provider status with major insurers.
Dr. Thomas is chief medical officer at the Renaissance Institute of Precision Oncology & Radiosurgery and has expertise in CNS and functional radiosurgery, SRS/SBRT, clinical trials, and an innovative radiotherapy joint therapy called Joint Glow. The company invites clinic owners and partners to inquire about licensing and integrating Adia Med regenerative therapies.
Adia Nutrition (OTCQB: ADIA) has engaged an independent accounting firm and securities counsel to prepare and file a Form 10 with the U.S. SEC, marking a move from OTC reporting to full SEC reporting.
The company expects to submit the Form 10 by end of November 2025, notes an SEC review/recognition period of 60 days, and anticipates the filing becoming effective by late January 2026. Full reporting will require audited financials, regular disclosures, and enhanced governance and is presented as a step toward meeting Nasdaq listing requirements and attracting institutional and accredited investors.
Adia Nutrition (OTCQB: ADIA) reported preliminary Q3 results for the quarter ended September 30, 2025 showing a revenue increase of more than 100% quarter‑over‑quarter and a profit margin exceeding 20%. Growth was attributed to higher sales of umbilical cord stem cells and exosome therapies across clinical partnerships, direct‑to‑consumer channels, and national expansion. Management described the quarter as a milestone for the company and said full reviewed financial statements will be posted on OTC Markets and filed by on or before November 15, 2025.
Contact and partnership inquiries directed to CEO Larry Powalisz.